EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mesenchymal stromal/stem cell-derived extracellular vesicles as a cell-free therapeutic strategy for traumatic brain injury

Ye Xiong, Yanlu Zhang, Zheng Gang Zhang, Michael Chopp

Brain Medicine · 30.06.2026 · 1-18

DOI: 10.61373/bm026i.0048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Medicine, erschienen am 30.06.2026. Verfasst von Ye Xiong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Henry Ford Health, Detroit, MI 48202, USA. Die Arbeit nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traumatic brain injury (TBI) is a leading cause of death and long-term neurological disability worldwide. Beyond the initial sudden mechanical insult, TBI is increasingly recognized as a chronic, multisystem disorder involving complex interactions among neurovascular, immune, and metabolic responses. This perspective helps explain the limited success of single-target neuroprotective therapies and underscores the need for multimodal regenerative strategies. Mesenchymal stromal/stem cells (MSCs) have emerged as promising therapeutic candidates for TBI due to their immunomodulatory and reparative properties, which are largely mediated by their secretome, particularly MSC-derived extracellular vesicles (MSC-EVs). These nanoscale vesicles carry selectively packaged nucleic acids, proteins, metabolites, and lipids from their parent cells, which mediate intercellular communication and induce repair pathways in recipient cells. Accumulating evidence indicates that MSC-EVs can reduce apoptosis and inflammation, promote angiogenesis, neurogenesis, and synaptic plasticity, and improve functional recovery following TBI. This review examines the current understanding of the multiscale pathophysiology of TBI and the role of brain-derived EVs in mediating crosstalk between the injured brain and peripheral systems in post-TBI multiorgan dysfunction, the translational potential of MSC-EVs in TBI, with a focus on EV cargo engineering, targeted delivery mechanisms, emerging therapeutic strategies, combinatorial regenerative strategies, as well as the growing role of artificial intelligence (AI)-assisted bioengineering in optimizing EV-based therapeutics, and considers future research directions that may facilitate clinical translation.

Schlagwörter

Stichwörter der Autor:innen

blood-brain barriercargo engineeringexosomesextracellular vesiclesmesenchymal stromal/stem cellsneuroinflammationtherapeutic approachtraumatic brain injury

Autor:innen und Institutionen

  • Department of Neurosurgery, Henry Ford Health, Detroit, MI 48202, USA.
  • Department of Physiology, College of Human Medicine, Michigan State University, Lansing, MI 48824, USA.
  • Department of Neurology, Henry Ford Health, Detroit, MI 48202, USA.
  • Department of Physics, Oakland University, Rochester, MI 48309, USA.

Förderung

  • NINDS NIH HHS

Zitieren

APA

Xiong, Y., Zhang, Y., Zhang, Z. G., & Chopp, M. (2026). Mesenchymal stromal/stem cell-derived extracellular vesicles as a cell-free therapeutic strategy for traumatic brain injury. Brain Medicine, 1-18. https://doi.org/10.61373/bm026i.0048

Vancouver

Xiong Y, Zhang Y, Zhang ZG, Chopp M. Mesenchymal stromal/stem cell-derived extracellular vesicles as a cell-free therapeutic strategy for traumatic brain injury. Brain Medicine. 2026:1-18. doi:10.61373/bm026i.0048

BibTeX
@article{Xiong2026,
  author = {Xiong, Ye and Zhang, Yanlu and Zhang, Zheng Gang and Chopp, Michael},
  title = {Mesenchymal stromal/stem cell-derived extracellular vesicles as a cell-free therapeutic strategy for traumatic brain injury},
  journal = {Brain Medicine},
  year = {2026},
  pages = {1--18},
  doi = {10.61373/bm026i.0048}
}
Kostenlos starten →